In gene therapy of Adenosine Deaminase (ADA) deficiency, the patient requires periodic infusion of genetically engineered lymphocytes because :
Retroviral vector is introduced into these lymphocytes.
Gene isolated from marrow cells producing ADA is introduced into cells at embryonic stages
Lymphocytes from patient's blood are grown in culture, outside the body.
Genetically engineered lymphocytes are not immortal cells.
Option (4) is the correct answer as genetically engineered lymphocytes are not immortal cells and die after some time. Option (3) is not the correct answer as the lymphocytes from patient's blood are grown in culture, outside the body but it is not the correct reason. In option (2), if the gene isolated from bone marrow cells producing ADA is introduced into cells at early embryonic stages, it could be a permanent cure.
Join thousands of students and practice with AI-generated mock tests.